Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment.
Status:
Completed
Trial end date:
2020-09-22
Target enrollment:
Participant gender:
Summary
The therapeutic scenario of metastatic renal cancer is undergoing a new revolution with the
appearance of a novel therapeutic strategy after the antiangiogenic treatments, that is the
immunotherapy, in addition to the approval of new active drugs in the following lines of
treatment.
There are currently two phase III trials in the first line of treatment in metastatic renal
cancer that include different combinations of treatment based on immunotherapy. If results of
these studies were positive, the therapeutic algorithm would be modified so that the
remaining drugs would have to be repositioned within the therapeutic decision scheme.
Sunitinib has previously demonstrated its benefit in patients who had failed to prior
treatment with cytokines, so it is likely to continue to be effective in patients who have
become resistant to treatment with new drugs based on immune checkpoint blockade.
This phase II study is developed to evaluate the activity of sunitinib after treatment with
immunotherapy-based regimens that are currently being developed within phase III clinical
trials.